Sermo’s newest and most revolutionary tool, Drug Ratings, was recently named by PM360 as one of 2017’s most innovative products!
PM360’s Innovations Issue was established six years ago to serve as a comprehensive guide of the year’s most innovative companies, divisions, startups, services, and strategies.
In May 2017, Sermo, the global social network for physicians with more than 800,000 members worldwide, announced the new “Drug Ratings” tool. Integrated into the network, Drug Ratings is the first and only global peer-to-peer prescription drug review system sourced exclusively from verified licensed physicians. Drug Ratings gives physicians a clinical decision support tool in which they can research, rate, and share their direct experience on the efficacy, safety, tolerability, accessibility, and adherence of specific drugs in real time. The Drug Ratings database has more than doubled in size since its initial release and now contains more than 440,000 drug ratings from global, licensed physicians.
This prestigious honor is awarded to software, apps, programs, and anything else designed to improve how those working in the industry do their jobs.
Hello, we’re Sermo! We appreciate you checking out our blog post about Sermo’s PM360 2017 Innovator Award. This exclusive award was presented to Sermo for our revolutionary peer-to-peer Drug Ratings tool for being one of 2017’s most innovative products.
We turn physician experience, expertise, and observations into actionable insights for the global healthcare community. Engaging with more than 1 million HCPs across 150 countries, we provide physicians with a social platform that fosters impactful peer-to-peer collaboration & discussions about issues that are important to them and their patients. Sermo offers on demand access to physicians via a suite of propietary technology to provide business intelligence that benefits pharmaceutical, healthcare partners and the medical community at large.